GeneTherapyLive’s Weekly Rewind – September 24, 2021

Article

Review top news and interview highlights from the week ending September 24, 2021.

Welcome to GeneTherapyLive’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.

1. HIV Gene Therapy Gets Go-Ahead for Early-Phase Trial

The FDA has accepted the investigational new drug application for EBT-101, an investigational CRISPR-based gene therapy for the potential treatment of human immunodeficiency virus (HIV). Excision BioTherapeutics will initiate a phase 1/2 clinical trial later in 2021.

2. Challenging Paradigms in AMD: Gregory S. Hageman, PhD

The executive director of the Steele Center for Translational Medicine at the Moran Eye Center discussed his team’s research in the role of HTRA1 and touched on current avenues of research for the gene.

3. OpRegen's Continued Efficacy in Dry AMD Geographic Atrophy

Brian Culley, chief executive officer, Lineage Cell Therapeutics, discussed updated data from the phase 1/2 study of OpRegen that demonstrated anatomical and functional improvements in geographic atrophy (GA).

4. Selecting Cell Therapy Targets in Cancer

The chief executive and medical officers of Cytovia Therapeutics discussed the company's therapeutic targets, including GPC3 in solid tumors, CD38 in hematologic malignancies, and EGFR in renal cancer, as well as the company’s cell therapy scaffold.

5. Cilta-Cel Continues to Show Durable Efficacy in Multiple Myeloma

Updated data from the phase 1b/2 CARTITUDE-1 trial (NCT03548207), presented during the 2021 SOHO Annual Meeting, continue to demonstrate ciltacabtagene autoleucel's (cilta-cel) efficacy and safety in pretreated patients with multiple myeloma, with an overall response rate (ORR) of 97.9% at a median follow-up of 18 months.

Recent Videos
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology
Jamie Jacobs, PhD, the program director of the center for psychiatric oncology & behavioral sciences at Mass General Cancer Center
Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology
Sarah Hein, PhD, the chief executive officer and cofounder of March Biosciences
Kiran Musunuru, MD, PhD, a physician-scientist and Barry J. Gertz Professor for translational research in the Perelman School of Medicine at the University of Pennsylvania and CHOP and Rebecca Ahrens-Nicklas, MD, PhD, a physician-scientist and director of the Gene Therapy for Inherited Metabolic Disorders Frontier Program at CHOP
Kiran Musunuru, MD, PhD, a physician-scientist and Barry J. Gertz Professor for translational research in the Perelman School of Medicine at the University of Pennsylvania and CHOP and Rebecca Ahrens-Nicklas, MD, PhD, a physician-scientist and director of the Gene Therapy for Inherited Metabolic Disorders Frontier Program at CHOP
Related Content
© 2025 MJH Life Sciences

All rights reserved.